Nnc0142-0002 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01181050 (ClinicalTrials.gov) | August 2010 | 12/8/2010 | Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA) | A Randomised, Single-dose, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0142-0002 in Subjects With Active Rheumatoid Arthritis | Inflammation;Rheumatoid Arthritis | Drug: NNC0142-0002;Drug: placebo | Janssen Research & Development, LLC | NULL | Completed | 18 Years | 75 Years | All | 63 | Phase 2 | Germany;Russian Federation;Ukraine |
| 2 | NCT00927927 (ClinicalTrials.gov) | June 2009 | 24/6/2009 | First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis | A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis | Inflammation;Rheumatoid Arthritis | Drug: NNC0142-0002;Drug: placebo | Janssen Research & Development, LLC | NULL | Completed | 18 Years | 75 Years | All | 65 | Phase 1 | Germany |